Emcure Pharmaceuticals Limited (NSE:EMCURE)
India flag India · Delayed Price · Currency is INR
2,334.40
+102.00 (4.57%)
Nov 12, 2026, 3:30 PM IST

Emcure Pharmaceuticals Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
10,9359,2446,8134,9825,3206,622
Depreciation & Amortization
4,1714,0203,7433,0322,5122,348
Other Amortization
130.17130.1797.9892.5689.04100.28
Loss (Gain) From Sale of Assets
-16.952.34-382.35-71.923.334.08
Loss (Gain) From Sale of Investments
5.13-15.24-58.04-25.32-1.21-
Stock-Based Compensation
54.1728.2919.8939.6752.7657.16
Other Operating Activities
1,0711,3272,5262,4192,4151,469
Change in Accounts Receivable
-3,773-4,261-1,434-1,506-3,398-1,729
Change in Inventory
-1,546-3,838-4,067-267.61663.85-3,072
Change in Accounts Payable
2,6232,7651,7021,543-391.83,157
Change in Other Net Operating Assets
42.2532.37-443.61736.2203.54-1,276
Operating Cash Flow
13,6969,4358,51710,9727,4697,682
Operating Cash Flow Growth
83.17%10.78%-22.38%46.91%-2.78%9.05%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-4,771-3,606-2,218-2,758-3,906-3,782
Sale of Property, Plant & Equipment
33.6142.6306.01315.3712.7531.21
Cash Acquisitions
-7,589-7,249--3,451--2,751
Sale (Purchase) of Intangibles
-2,533-1,871-1,852-313.6-127.67-187.87
Investment in Securities
178.56734.942,592-1,098-708.36-1,308
Other Investing Activities
12.6517.72231.44179.46152.4109.49
Investing Cash Flow
-13,491-11,931-940.01-7,125-4,577-7,888

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
-4,303-1,025976.791,759
Long-Term Debt Issued
-2,500-5,4743,5763,714
Total Debt Issued
2,8616,803-6,5004,5535,473
Short-Term Debt Repaid
---5,225---
Long-Term Debt Repaid
--1,918-9,420-5,310-3,777-4,814
Lease Payments
-666.98-626.91-587.09-486.86-350.13-347.01
Total Debt Repaid
-3,250-1,918-14,645-5,310-3,777-4,814
Net Debt Issued (Repaid)
-389.54,884-14,6451,190775.24659.17
Issuance of Common Stock
135.8266.467,79276.6--
Common Dividends Paid
-682.92-568.53--542.55-361.71-542.55
Other Financing Activities
-3,454-947.89-1,287-2,366-1,868-1,635
Financing Cash Flow
-4,3903,434-8,140-1,642-1,454-1,519

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
95.3181.55-20.49-20.02-1.281.86
Miscellaneous Cash Flow Adjustments
-----1002,141
Net Cash Flow
-4,0901,121-583.022,1851,336418.7

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
8,9255,8306,2998,2153,5633,900
Free Cash Flow Growth
75.92%-7.45%-23.32%130.58%-8.65%-32.65%
Free Cash Flow Margin
8.72%6.33%7.98%12.34%5.95%6.66%
Free Cash Flow Per Share
47.0430.7633.6845.4219.7021.57
Levered Free Cash Flow
824.583,2382,7773,6701,6252,297
Unlevered Free Cash Flow
1,5393,9043,5914,9402,7813,216
Free Cash Flow After Leases
8,2585,2035,7127,7283,2123,553

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
1,130947.891,2872,0821,7861,553
Cash Income Tax Paid
4,7293,6812,4692,2372,0053,112
Change in Working Capital
-2,654-5,301-4,243505.17-2,922-2,919